{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-008031","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.323735+00:00","generated_at":"2026-06-14T00:57:43.488328+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pharma-Bio Serv Q2 net income rises to $0.4M; revenue falls 8% to $4.6M","bullets":["Revenue for three months ended Apr 30, 2023: $4.6M, down $0.4M YoY.","Net income for Q2 was $0.4M, up $0.2M from prior year; H1 net income $0.8M, up $0.3M.","Gross profit margin improved 5.0 percentage points in Q2 and 4.8 ppts in H1.","CEO cites strategy to focus on most profitable markets and grow presence."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-008031","json":"https://secwatch.observer/filing/0001654954-23-008031.json","markdown":"https://secwatch.observer/filing/0001654954-23-008031.md","text":"https://secwatch.observer/filing/0001654954-23-008031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423008031/0001654954-23-008031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423008031/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T00:57:43.488328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c0e9354f8240c13b9da84c8c4f7ebd401bf052e","claim":"Pharma-Bio Serv, Inc. reported the three and six months ended April 30, 2023 results: revenue approximately $4.6 and $8.8 million, respectively, net income approximately $0.4 and $0.8 million, respectively.","evidence_excerpt":"revenues for the three and six months ended April 30, 2023 were approximately $4.6 and $8.8 million, respectively, a decrease of approximately $0.4 and $1.2 million, respectively, when compared to the same periods last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495423008031/0001654954-23-008031-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended April 30, 2023"},{"label":"Revenue","value":"approximately $4.6 and $8.8 million, respectively"},{"label":"Net income","value":"approximately $0.4 and $0.8 million, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}